Johnson and Johnson made it clear in its statement that their experimental vaccines have failed to provide apt protection against HIV in the Sub-Saharan Africa region, to the young one who are most likely at a high risk of being infected. As vaccines show a mid-stage failure it does highlight the challenges of vaccines development. That too for a disease like the Human immunodeficiency virus, which certainly has no approved vaccine so far. In the statement by Paul Stoffels, J&J Chief, he said, “HIV is a unique and complex virus that has long posed unprecedented challenges for the vaccine development because of its ability to hijack, attack and evade the human immune system”.
The study in which the vaccines were tested included 2600 women participants, from across five Southern African countries, where women and girls are accounted for more than 60% of all new HIV infections last year. After this, the study is not to be continued, based on the data received, as per Johnson and Johnson. Also, the participants of the study will be informed about the received results and will be told whether they received a placebo or vaccine.